1. Home
  2. Nation
  3. Over 2.11 crore COVID vax vails available with states, UTs and private hospitals: Centre

Over 2.11 crore COVID vax vails available with states, UTs and private hospitals: Centre

By Saima Siddiqui 
Updated Date
Over 2.11 crore COVID vax vails available with states, UTs and private hospitals: Centre

New Delhi: Rubbishing the news of vaccine stock scarcity at several vaccination centres, the Union health ministry on Tuesday claimed that more than 2.11 crore COVID-19 vaccine doses are still available with states and union territories, and private hospitals.

Also Read :- Indonesia’s Covid-19 toll breaches 1 lakh mark; 1,747 deaths in last 24 hrs

Over 42.15 crore (42,15,43,730) vaccine doses have been provided to states and union territories (UTs) so far, through all sources, and 71,40,000 doses are being supplied, it said.

Of this, the total consumption, including wastage, is 40,03,50,489 doses, according to data available at 8 am, the ministry said.

It said that 2,11,93,241 balance and unutilised COVID-19 vaccine doses are still available with states and UTs, and private hospitals.

The Union government is committed to accelerate pace and expansion of the scope of the COVID-19 vaccination throughout the country, the ministry said.

Also Read :- Covid 2nd wave still raging, R-value up in 8 states, UTs; Govt calls it cause of concern

The new phase of universalisation of COVID-19 vaccination started from June and the inoculation drive has been ramped up through availability of more vaccines, advance vaccine availability to states and UTs for enabling better planning by them and streamlining of the supply chain, according to the ministry.

It said that as part of the nationwide vaccination drive, the Centre has been supporting states and UTs by providing them vaccines free of cost.

In the new phase, the government will procure and supply at no cost 75 per cent of the vaccines being produced in the country to states and UTs, according to the ministry.

Further reading:
For the latest news and reviews, follow us on Facebook and Twitter ...
X